Synergy Pharmaceuticals, Inc. (SGYP) Receives $7.84 Consensus Price Target from Analysts

A sudden increase in a stock's activity can be a sign that investors are trading in anticipation of a catalyst, or that investors feel very strongly in one way or the other about the future direction of a stock. Great West Life Assurance Co Can invested in 0% or 22,700 shares. Vanguard Group Inc. now owns 17,422,326 shares of the biopharmaceutical company's stock valued at $77,530,000 after buying an additional 1,636,563 shares during the last quarter. (NYSE:TIF) valuations. The stock trades on a P/S of 3.25, which suggests that the shares are attractive compared with peers. (NASDAQ:SGYP) for 945,186 shares. Oppenheimer downgraded Synergy Pharmaceuticals Inc. The Kansas-based Creative Planning has invested 0% in Synergy Pharmaceuticals Inc. Guggenheim Ltd Co reported 0% in Synergy Pharmaceuticals Inc. (P) is 2.33. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. On Wednesday, May 31 the stock rating was maintained by BTIG Research with "Buy". Principal Fincl Gru reported 35,189 shares. (NASDAQ:SGYP) has an average volume of 7.02 Million. After $2.86 actual EPS reported by NetEase, Inc. for the previous quarter, Wall Street now forecasts -15.73% negative EPS growth. Cubist Systematic Strategies Ltd Limited Liability Company has 21,381 shares. Closing price generally refers to the last price at which a stock trades during a regular trading session.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) institutional sentiment increased to 1.9 in 2017 Q3. Metropolitan Life Insur Ny stated it has 0% in Synergy Pharmaceuticals Inc. To measure price-variation, we found TIF's volatility during a week at 1.47% and during a month it has been found around 1.79%.

Synergy Pharmaceuticals (SGYP) opened at $2.18 on Thursday. Raymond James Financial Services Advisors Inc. raised its holdings in Synergy Pharmaceuticals by 13.9% in the 2nd quarter. They expect $-0.20 EPS, up 35.48 % or $0.11 from last year's $-0.31 per share.

Here's what's interesting to note about Synergy Pharmaceuticals Inc. Moreover, Kingdon Cap Ltd Limited Liability Company has 0.15% invested in Synergy Pharmaceuticals Inc. It has outperformed by 7.74% the S&P500. OxFORD Asset Management LLP acquired a new position in Synergy Pharmaceuticals in the second quarter valued at approximately $6,372,000. (NASDAQ:SGYP). Morgan Stanley invested in 1.99M shares. (NASDAQ:SGYP). Axiom Intll Investors Ltd Liability Com De reported 760,518 shares.

Oppenheimer has given Synergy Pharmaceuticals (NASDAQ:SGYP) shares a new "Perform" rating in an analyst report issued to clients on Friday morning. Therefore 75% are positive. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. The firm has a market cap of $480.42, a price-to-earnings ratio of -1.88 and a beta of 1.22. On Friday, September 8 the stock rating was maintained by Cantor Fitzgerald with "Buy".

UP Haj house repainted to original, govt blames contractor for saffron
A section of Muslims and some opposition parties have objected to the Haj House exterior being painted saffron . The committee also manages the UP Haj House that is located near the Lucknow airport on Kanpur road.

Winning Mega Millions ticket sold in Florida
The Mega Millions numbers Friday night were 28, 30, 39, 59, 70 and the Mega Ball was 10. A winning Mega Millions ticket was drawn Friday night for the $450 million jackpot.

Traders Purchase Large Volume of Western Gas Partners Put Options (NYSE:WES)
Neuberger Berman Limited Liability Corporation holds 0.59% in Western Gas Equity Partners, LP (NYSE:WGP) or 11.54M shares. Morgan Stanley initiated Western Gas Partners, LP (NYSE:WES) on Thursday, February 25 with "Equal-Weight" rating.

Since January 1, 0001, it had 0 buys, and 1 insider sale for $98,972 activity. During the same quarter in the previous year, the company earned ($0.22) earnings per share. sell-side analysts anticipate that Synergy Pharmaceuticals will post -1.04 EPS for the current fiscal year. The shares were sold at an average price of $2.82, for a total transaction of $24,675,000.00.

Heading into the stock price potential, Synergy Pharmaceuticals Inc. needs to grow just 182.26% to cross its median price target of $7. (NYSE:DYN) by 0.24% during the September 2017 quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.

In order to determine directional movement, the 50-day and 200-day moving averages for Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals had 34 analyst reports since August 25, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with "Buy" on Wednesday, October 11. The company was maintained on Friday, December 23 by Rodman & Renshaw. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. As per Thursday, June 1, the company rating was initiated by Cantor Fitzgerald. Cantor Fitzgerald has "Buy" rating and $10.0 target. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.